Analyzing IHC Data: From HALO Software to Pathologist Review

Overview of IHC Data Analysis

IHC analysis involves evaluating stained tissue samples to derive meaningful data, ranging from visual assessments to fully digital outputs. This process enables researchers to detect target antigens in cells in terms of presence, location, and protein expression levels.

There are several types of immunohistochemistry methods, each suited for different study goals. These include chromogenic methods using reporter enzymes, fluorescent detection using labeled antibodies, and multiplex staining workflows. Choosing the appropriate immunohistochemistry method depends on factors such as tissue type, antigen abundance, and the level of quantification needed.

Reliable interpretation of IHC data is critical in drug development and translational research, reliable IHC analysis is essential for making data-driven decisions about efficacy, safety, and mechanism of action. Proper controls such as normal serum, positive controls and negative controls help ensure specificity and reduce cross-reactivity, especially in frozen sections. Blocking endogenous peroxidase activity is also critical when using enzyme-based detection systems to avoid non-specific background staining. Establishing both positive control and negative control groups is a standard part of quality control protocols in IHC workflows.

Depending on study design requirements, results may be interpreted manually by trained pathologists or through digital image analysis platforms like HALO and QuPath. Each IHC method offers distinct advantages, and selecting the appropriate IHC analysis method can significantly impact data reproducibility and downstream application.

Manual IHC Analysis: Traditional Approaches

Manual IHC analysis is still widely used in clinical diagnostics and regulatory studies. It relies on visual scoring of slides by scientists or certified pathologists using a light microscope. This form of light microscopy enables detailed evaluation of tissue morphology and staining patterns, which is critical for interpreting immunohistochemical staining results.

Common scoring systems, such as H-score and Allred score, evaluate both immunohistochemical staining intensity and the percentage of positive staining cells. Manual review adds important context, allowing the observer to identify artifacts, assess tissue morphology, and manage edge effects. These reviews often incorporate primary antibodies targeting specific antigens, followed by detection using secondary antibodies conjugated with reporter systems like Alkaline Phosphatase.

The indirect method, which uses a secondary antibody to detect a primary antibody bound to the antigen, is commonly used due to its flexibility and signal amplification advantages. In contrast, the Direct method, where the label is conjugated directly to the primary antibody, is sometimes used for simpler assays or where minimal background is needed. Careful management of secondary antibody reactions is important to avoid background signal and ensure specificity, especially in multiplex or enzyme-based systems.

Prior to staining, appropriate antigen retrieval methods are applied to expose epitopes masked by chemical fixation, improving antibody binding efficiency. To ensure reliable interpretation, each batch typically includes a positive control sample for validation and a negative control for background assessment, which are critical components of IHC quality control.

Digital IHC Analysis: HALO, QuPath, and beyond

Automated IHC analysis uses high-resolution imaging and algorithm-based software to quantify staining results. Platforms like HALO, QuPath, and more enable objective, high-throughput processing of IHC data. These systems also support standardized workflows using validated monoclonal antibodies and secondary antibodies to ensure reproducibility.

When working with frozen sections, it's critical to address cross-reactivity and background by applying normal serum as a blocking agent and using appropriate negative controls in each batch for quality control. Optimizing the antigen retrieval technique is crucial in digital IHC workflows, as it significantly impacts signal intensity and the quality of image-based quantification. Common antigen retrieval processes involve heat or enzymatic treatment (e.g., with Citrate buffer) to reverse formalin-induced protein cross-links and unmask the antigen in tissue sections.

Advanced digital platforms integrate metadata related to primary antibodies and their interaction with polyclonal antibody reagents, reducing false positives and enhancing signal clarity in immunohistochemical staining. While automated tools improve quantification, light microscopy is often still used in parallel to verify findings visually and to identify subtle structures in biological tissue that algorithms may overlook.

For fluorescence-based assays, a fluorescence microscope or confocal microscope may be required to validate spectral separation and confirm localization using fluorescent antibodies. In some cases, visualization depends on reporter enzymes reacting with a chromogenic substrate to produce a visible signal. In more advanced workflows, avidin-biotin complexes or biotinylated antibody systems may be used for enhanced detection. Some researchers may also use tyramide signal amplification to improve sensitivity when detecting low-abundance targets.

Previous studies have shown that combining pathologist visual review with automated tools yields better accuracy in ambiguous cases. Additionally, these tools can support the use of tissue microarrays for large-scale screening of multiple biomarkers in parallel.

Digital immunohistochemistry methods improve speed, consistency, and depth of analysis, particularly in studies with large sample sizes or multi-marker panels. These methods are especially effective when combined with automated primary antibodies and secondary antibodies staining protocols, and workflows involving enzymes like horseradish peroxidase or labels used in fluorescence microscopy. Their ability to analyze enzyme activity at high resolution makes them a powerful technique in modern IHC workflows.

Pathologist Review: When & Why It Matters

While digital IHC analysis offers speed and consistency, there are many situations where a pathologist visual interpretation is either required or highly beneficial. Pathologists bring critical context to the analysis, recognizing artifacts, distinguishing between cell types, and providing nuanced scoring that algorithms alone may miss.

Pathologist review is particularly important in the following scenarios:

• Regulatory studies (GLP, IND-enabling): Pathologist-signed reports may be required for submission.
• Ambiguous or borderline staining: Subtle expression differences may need expert clarification.
• Rare tissue types or complex histology: A trained eye can provide insights that algorithms can’t detect.
• Clinical trials and biomarker qualification: Human judgment ensures reliable context alongside statistical analysis of findings.

Communicating Your Analysis Needs to a CRO

Clear, detailed communication is one of the most effective ways to prevent delays and misalignment when outsourcing IHC analysis to a Contract Research Organization (CRO).

Vague requests often lead to incomplete quotes, repeated clarification emails, and incorrect assumptions that can derail timelines, especially in regulatory or IND-enabling studies.

To ensure smooth execution and accurate data output, it’s critical to specify your analysis requirements upfront. The more structured and precise your initial scope of work, the more likely you are to receive fast, relevant, and cost-effective proposals from CROs.

Here are key elements to include in your request for IHC analysis:

• Manual vs. digital analysis: Clearly state your preference and if digital, name the software (e.g., HALO, QuPath).
• Scoring method: Indicate if you require H-score, Allred score, percent positivity, or custom metrics.
• Quantification level: Specify whether you need cell-level, tissue-level, or region-based analysis.
• Region of interest (ROI): Let the lab know if you'll define ROIs or want them selected automatically.
• Pathologist review: Mention whether expert interpretation is required, optional, or not needed.

Whenever possible, attach reference documents, prior study protocols, or sample images to provide context. These materials can help the CRO align its technical approach with your expectations and ensure regulatory or publication readiness from the start.

If you’re submitting to multiple CROs, use a standardized request template to ensure fair, side-by-side comparison of quotes. This is especially useful in vendor selection processes involving budget justification, GLP compliance, or internal review boards.

Best Practices for High Quality IHC Data

Immunohistochemistry (IHC) is a sensitive technique that relies on multiple interdependent steps. Inconsistent handling at any stage can compromise specificity, sensitivity, and reproducibility. The following best practices provide a reliable framework for designing and conducting high-quality IHC studies:

Standardize tissue handling and fixation

Ensure that tissue samples are consistently fixed using validated protocols (e.g., 10% neutral buffered formalin, 24–48 hours). Over- or under-fixation can mask epitopes or damage tissue morphology, affecting antibody binding and staining quality.

Select the appropriate antigen retrieval method

Use either heat-induced epitope retrieval (HIER) or enzymatic digestion, depending on the fixation method and antigen type. For example, Citrate buffer (pH 6.0) or EDTA (pH 9.0) are commonly used for HIER. Optimization may be needed for each antibody-tissue pair.

Use validated primary antibodies

Choose antibodies with established specificity for your target antigen. Look for validation in peer-reviewed publications or datasheets, ideally with application-specific evidence for IHC on the relevant tissue type (e.g., FFPE or frozen).

Ensure compatibility of secondary antibodies and detection systems

Select secondary antibodies raised against the host species of the primary antibody. Confirm that the detection system—enzyme-conjugated (e.g., horseradish peroxidase, alkaline phosphatase) or fluorophore-labelled—is appropriate for your analysis platform and signal readout.

Titrate antibody concentrations carefully

Perform dilution series to identify the concentration that provides a strong, specific signal without background staining. Over-concentration may cause non-specific binding, while under-concentration can reduce sensitivity.

Include comprehensive controls in each batch

Controls are essential for validating staining quality and interpretation:

• Positive controls: Tissue known to express the target antigen.
• Negative controls: Tissue lacking the target antigen.
• Isotype controls: Non-specific antibodies matched in species and isotype to the primary antibody, used to assess background binding.
• No-primary controls: Omitting the primary antibody to confirm absence of non-specific signal from the secondary.

Apply blocking steps to reduce background

Use blocking solutions such as normal serum, BSA, or commercial blockers to reduce non-specific binding. For enzyme-based detection, block endogenous peroxidase or alkaline phosphatase activity using hydrogen peroxide or levamisole, respectively.

Avoid cross-reactivity in multiplex IHC

When detecting multiple targets, use antibodies from different host species and validate them individually and in combination. Include controls for each target to ensure specificity is maintained when multiplexed.

Document incubation conditions precisely

Record antibody incubation times, temperatures, and buffer compositions. Small changes in these parameters can significantly affect staining outcomes and reproducibility.

Calibrate and validate digital image analysis platforms

For automated quantification, periodically calibrate imaging systems and validate software algorithms using known standards. Variability in lighting, resolution, or algorithm tuning can lead to inaccurate quantification.

Monitor reagent quality and batch-to-batch variability

Track the lot numbers of critical reagents (e.g., antibodies, detection kits) and assess consistency across lots. Inconsistent batches can cause drift in staining intensity or specificity, compromising comparative studies.

Integrate digital scoring with expert visual review

While image analysis software (e.g., HALO, QuPath) provides objectivity and scalability, pathologist review remains essential, especially for identifying artifacts, verifying cellular context, and interpreting ambiguous cases.

Choosing the Right Method for Your Study

The choice of immunohistochemistry (IHC) method needs to align with your study goals, tissue specimen type, and analysis platform. Chromogenic detection is well-suited for visual assessment in brightfield microscopy, while fluorescence-based methods support multiplexing and quantitative analysis.

Direct detection uses labeled primary antibodies for a faster workflow but lower signal strength. Indirect detection, involving labeled secondary antibodies, enables stronger signal amplification and greater flexibility.

Antibody selection also matters. Monoclonal antibodies provide high specificity, ideal for single-target detection. Polyclonal antibodies, with broader epitope recognition, are better suited for detecting low-abundance or masked antigens.

Tissue sections prepared from FFPE or frozen tissues require different approaches. FFPE samples often need heat-induced epitope retrieval to unmask antigens, while frozen tissues preserve antigenicity but may compromise tissue structure.

In multiplex IHC, selecting primary antibodies from different species and using non-overlapping fluorophores is essential to avoid cross-reactivity. Signal amplification techniques like avidin-biotin complexes or tyramide signal amplification (TSA) improve sensitivity but demand tight control of background. Methods should also be compatible with digital analysis platforms such as HALO or QuPath, which require uniform, high-contrast staining. Pilot testing is strongly recommended to validate antibody performance and staining consistency before scaling up.

Need support with IHC analysis?

Whether you’re exploring protein expression, validating preclinical targets, or preparing submission-ready IHC data for an IND filing, Boster Bio provides full-service IHC support tailored to your research goals.

We offer both manual pathologist visual review and digital IHC analysis using HALO-compatible workflows. Our experienced team can help you select appropriate immunohistochemistry methods, define regions of interest, and deliver clear, quantitative data you can trust!

Get a Quote from Boster Bio